There are 2789 resources available
1202P - ALK-2016-CPHG: French cohort of advanced non-small cell lung cancer (aNSCLC) with ALK (ALK+) or ROS1 (ROS1+) gene rearrangement treated by crizotinib
Presenter: Didier Debieuvre
Session: ePoster Display
1203P - The analysis of ALK fusion variants in 4991 EGFR/MET mutation-negative non-squamous non-small cell lung carcinomas (NSCLCs)
Presenter: Evgeny Imyanitov
Session: ePoster Display
1204P - Cost-benefit analysis of ALK diagnosis in patients with non-small cell lung cancer in Spain
Presenter: Ana Laura Ortega Granados
Session: ePoster Display
1205P - Treatment sequencing and duration of subsequent tyrosine kinase inhibitors in ALK+ non-small cell lung cancer patients treated with brigatinib in the US
Presenter: Mohammad Jahanzeb
Session: ePoster Display
1206P - UNcommon EGFR mutations: International Case series on efficacy of Osimertinib in Real-life practice in first-liNe setting (UNICORN)
Presenter: Jair Bar
Session: ePoster Display
1209P - RELAY, ramucirumab plus erlotinib (RAM+ERL) in untreated metastatic EGFR-mutant NSCLC (EGFR+NSCLC): Association between TP53 status and clinical outcome
Presenter: Makoto Nishio
Session: ePoster Display
1210P - Preclinical and preliminary clinical investigations of furmonertinib in NSCLC with EGFR exon 20 insertions (20ins)
Presenter: Baohui Han
Session: ePoster Display
1211P - Indirect comparison of mobocertinib and standard of care in platinum-pretreated patients with NSCLC with EGFR exon 20 insertion
Presenter: Sai-Hong Ou
Session: ePoster Display
1212P - Afatinib for the treatment of NSCLC with uncommon EGFR mutations: An updated database of 1023 cases
Presenter: James Yang Yang
Session: ePoster Display